All Posts Tagged With: "GSK"
(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues
Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate...
(ISIS) Isis Pharmaceuticals Reported Loss Widens
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents.
Revenues...
(VRTX) Vertex Pharmaceuticals Posts Wider Loss
Vertex Pharmaceuticals Inc. (VRTX) posted first-quarter 2011 loss (including stock-based compensation expense) of $1.05 per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss...
(THRX) Theravance Reports Earnings In Line With Estimates
Theravance Inc.’s (THRX) first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate but narrower than the year-ago loss of 35 cents per share. Earnings improvement was driven...
(GSK) GlaxoSmithKline and Valeant Pharmaceuticals Respond to CRL From FDA
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals (VRX) recently submitted a response to the Complete Response Letter (CRL) received from...
(MRK) Merck in Joint Venture with Sun Pharma
Merck & Co., Inc. (MRK) recently announced that it is setting up a joint venture (JV) with Indian multinational pharma company, Sun Pharmaceutical Industries Ltd. The joint venture is for the development,...
(ALNY) Alnylam Pharmaceuticals Signs IP Deal with NYU
Alnylam Pharmaceuticals Inc. (ALNY) recently announced that it has received an exclusive license from the New York University (NYU) for intellectual property covering therapeutic uses of miR-33a and miR-33b...
(ISIS) Isis Pharmaceuticals Analyst Retains Neutral on Shares
We recently reiterated a Neutral recommendation (Zacks #3 Rank – short-term “Hold” rating) on Isis Pharmaceuticals (ISIS). Isis Pharma is a drug discovery and development company that focuses on the...
(GSK) Company News for April 08, 2011 – Corporate Summary
• Bed Bath & Beyond Inc.’s (NASDAQ:BBBY) shares rose 10.5% a day after the retailer projected earnings ahead of Wall Street’s expectations for the fiscal year ending in Feb. 2012
• Drug developer Immunogen...
(VVUS) Vivus’ Qnexa Weight Loss Candidate Reports Encouraging Study Data
Vivus, Inc. (VVUS) recently reported positive data from the SEQUEL study on its weight loss candidate, Qnexa. The 52-week SEQUEL study included 675 obese/overweight patients, who had two or more weight-related...
(LLY) Eli Lilly’s Axiron Testosterone Deficiency Drug Launched in the U.S.
Eli Lilly and Company (LLY) recently announced the availability of Axiron in pharmacies across the US. Axiron gained approval from the US Food and Drug Administration (FDA) in November 2010 for use as a replacement...
(THRX) Theravance Analyst Maintains Neutral on Shares
We are maintaining our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $25.00 after the company’s fourth quarter and fiscal year 2010 financial results.
Theravance’s...
(CMLS) Company News for March 11, 2011 – Corporate Summary
• Cumulus Media (NASDAQ:CMLS) reported that it has entered into a merger agreement to acquire all the outstanding common stock and warrants of Citadel Broadcasting Corp for $37 per share
• Starbucks (NASDAQ:
(VRX) Valeant Pharmaceuticals International’s Sales Benefit Post Merger
Valeant Pharmaceuticals International‘s (VRX) fourth quarter 2010 earnings of 46 cents per share missed the Zacks Consensus Estimate by a cent and was 45.2% below the year-ago earnings of 84 cents per share....
(JNJ) Pharmaceutical Industry Outlook – March 2011 – Industry Outlook
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
(AAPL) Company News for January 18, 2011 – Corporate Summary
• Comerica (NYSE:CMA) has plans to purchase Sterling Bancshares (NASDAQ:SBIB) for $1.03 billion for a deal worth $10 per share
19Jan2011 | vitalstocks | 0 comments | Continued(VVUS) Vivus Seeks EU Nod for Qnexa
Vivus, Inc. (VVUS) recently announced that it has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) seeking approval for Qnexa. The company is looking to get Qnexa...
(LLY) Eli Lilly and Company Gets FDA Approval of Axiron
Eli Lilly and Company (LLY) and partner Acrux recently announced good news in the form of US Food and Drug Administration (FDA) approval for Axiron. The FDA approved Axiron for use as a replacement therapy...
(ACN) Accenture Announces Plan to Acquire CRM Software Firm CAS Computer
Technology outsourcing and consulting major Accenture plc (ACN) recently announced its intention to acquire Germany-based customer relationship management (CRM) and mobility software provider CAS Computer...
(SHPGY) Shire Beats Earnings Expectations – Increases Earnings Outlook
Shire plc (SHPGY) posted earnings of $1.16 per American Depositary Share (ADS) during the third quarter of 2010, beating the Zacks Consensus Estimate of 98 cents and the year-ago earnings of 49 cents per...
(HGSI) Human Genome Sciences Earns FDA Panel Backing of Benlysta
Human Genome Sciences Inc. (HGSI) received a huge boost when its potential blockbuster candidate Benlysta received a positive recommendation from an advisory panel of the US Food and Drug Administration (FDA)....
(ISIS) Isis Pharmaceuticals Reports Loss Widens
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 13 cents per share in the third quarter 2010, wider than the year-ago loss of 12 cents. The higher loss was mainly due to higher operating expenses.
However,...
(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
(HGSI) Human Genome Sciences Reports Narrower Than Expected Earnings Loss
Human Genome Sciences Inc.’s (HGSI) third quarter 2010 loss of 22 cents per share was narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 32 cents. The narrower loss...
(VRTX) Vertex Pharmaceuticals Reports Wider Loss
Vertex Pharmaceuticals Inc. (VRTX) posted a higher third-quarter loss (including stock-based compensation expense) of 99 cents per share, compared with the Zacks Consensus Estimate of a loss of 91 cents and...
(THRX) Theravance Third Quarter 2010 Earnings Loss Wider Than Expected
Theravance Inc.’s (THRX) third quarter 2010 loss per share of $0.29 was $0.02 wider than the Zacks Consensus Estimate, but narrower than the year-ago quarter loss of $0.35.
Revenue at Theravance...
(PFE) Pfizer and Biocon Enter Gloabal Diabetes Deal
Pfizer (PFE) recently entered into a global agreement with Indian biotech company Biocon, for certain diabetes biosimilars. The deal relates to the global commercialization of biosimilar versions...
(CVD) Big Pharmaceutical Companies Outsourcing Research and Development
by Tony D’Altorio, Investment U Research
Thursday, October 14, 2010
Big...
(ABT) Abbott Labs Removes Obesity Drug Meridia From Market
Abbott Labs (ABT) recently announced its intention to pull obesity drug Meridia from the US market. Abbott Labs’ decision was based on a request made by the US Food and Drug Administration (FDA).
The...
(JNJ) Johnson & Johnson Announces Plans to Aquire Remaining Interest in Crucell NV
Johnson & Johnson (JNJ) recently announced its plans to buy out the rest of Dutch biopharmaceutical company Crucell NV (CRXL) for €1.75...